Clinical Trials in Georgia

Showing 7341-7360 of 19,050 trials

Growth and Tolerance of a Partially Hydrolyzed Infant Formula

NCT05047978

The purpose of this research study is to compare the growth and tolerance of infants who consume either an infant formula with intact proteins or an infant formula with partially hydrolyzed proteins through approximately 12 months of age.

Growth

Mead Johnson Nutrition244 participantsStarted Aug 2021

Birmingham, Alabama, United States • Dothan, Alabama, United States • Tucson, Arizona, United States +10 more locations

TERMINATEDPhase 1/265 miles

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

NCT02152956

Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three segments: the Single Patient Dose Escalation Segment (complete), followed by the Multi-Patient Dose Escalation Segment (complete) and the Maximum Tolerated Dose and Schedule (MTDS) Expansion Cohort Segment (closed). Having characterized safety and determined the maximum tolerated dose and schedule, the primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR or CRh. Starting with Cycle 2, patients who are benefiting from flotetuzumab may receive up to a maximum of 8 cycles of treatment. Patients will receive daily increasing doses of flotetuzumab for the first week of Cycle 1 (Lead-In Dosing) followed by 3 weeks of continuous intravenous infusion at a the assigned dose. Subsequent cycles are each 4 weeks of continuous infusion at the assigned dose. Dosing may continue for up to 8 cycles. Follow up visits may continue for 6 months after treatment is discontinued.

AML

MacroGenics244 participantsStarted Jun 2014

Duarte, California, United States • La Jolla, California, United States • San Francisco, California, United States +40 more locations

Growth and Tolerance of a Partially Hydrolyzed Infant Formula

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Find Trials by Condition in Georgia

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Incorporating Supersaturated Oxygen in Shock

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study of Mirikizumab in Participants With Plaque Psoriasis

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip